Early data from the company’s first human study of its next-generation Alzheimer’s treatment showed that it lowered levels of toxic amyloid plaques in the brains of people in the earliest stages of the mind-wasting disease.
https://www.pharmalive.com/wp-content/uploads/2020/10/Eli-Lilly-in-deal-to-supply-Covid-19-drugs-to-low-income-countries-Reuters-10-8-20.jpeg246370Reuters Healthhttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngReuters Health2023-03-31 08:32:002023-03-31 10:21:25Lilly says experimental Alzheimer's drug reduces amyloid in small study
